论文部分内容阅读
利福平(RFP)治疗矽肺结核优于一线抗痨药的临床资料已略有报导,而抗矽—14并用利福平的临床报告却尚未见到。为了观察国产利福平并用抗矽—14治疗矽肺结核的临床疗效,我们于1976年1～9月选择了10例矽肺结核病人进行了门诊治疗观察。利福平停药之后,继续用抗矽—14与链霉素和雷米封合用,同时增加了4例病人。现将10例矽肺结核病人治疗16个月的情况小结如下。 临床资料 一、一般情况 全部病人皆为男性,年令最小者44岁,最大者57岁,平均48.7岁。接尘工令最短者
Clinical data on rifampicin (RFP) treatment of silicotic TB better than first-line anti-tuberculosis drugs have been slightly reported, whereas clinical reports of anti-silico-14 concurrent rifampicin have not yet been reported. In order to observe the clinical efficacy of domestic rifampicin and anti-silicon-14 for the treatment of silicotic tuberculosis, we selected 10 cases of silicotic TB patients from January to September 1976 for outpatient treatment. After rifampicin withdrawal, continue to use anti-silicon-14 and streptomycin and ramie seal use, while an increase of 4 patients. Now 10 cases of silicosis patients treated for 16 months, the situation is summarized as follows. Clinical data First, the general situation All patients are men, the youngest 44 years old, the largest 57-year-old, an average of 48.7 years of age. Take the shortest dust workers